MOOLEC SCIENCE DL 1,50

At Moolec Science’s virtual annual general meeting, around 71.2% of the voting shares were represented. Shareholders approved the consolidated financial statements for the fiscal year ended June 30, 2025, and the report of the independent auditor. Four directors (Diego Abelleyra Llodra, Oscar Leon Bentancor, Romualdo Varela, Daniel Core) were re-elected, and Price Waterhouse & Co. S.R.L. was confirmed as the independent auditing firm for the year ending June 30, 2026; all resolutions were passed by more than a simple majority. » More on de.investing.com

Moolec Science has finished its 2026 commercial planting campaign for the GLASO1 safflower program in the American Falls, Idaho area and expects stands to establish over the coming weeks. The company identified 52 elite genotypes averaging more than 60% GLA from 320 candidates; previously measured GLA concentrations at processing were about 45%. Moolec prepared fields using optimized soil and irrigation protocols and said it will continue testing the selected lines on research plots as the company approaches the May 28 financial results. » More on de.investing.com

Moolec Science has completed the first industrialization phase of its Saflor platform GLASO1 and confirmed commercialization at around 45% gamma-linolenic acid (GLA) on an industrial scale. The 2025 campaign exceeded internal expectations, delivered a high-purity GLA yield and a market-ready end product with initial demand from the animal feed industry. The company is advancing the 2026 GLASO1 campaign, starting sowing in early May and partnering with a global agribusiness and food company. Financial analysts point to a weak overall balance sheet, low gross margins and high share-price volatility; market capitalization remains small. » More on de.investing.com